OKYO Pharma Limited (OKYO) Max Pain Analysis
Max pain is the strike price where aggregate option buyer payout is minimized at expiration. It represents the price at which option writers retain the most premium.
OKYO Pharma Limited (OKYO) operates in the Healthcare sector, specifically the Biotechnology industry, with a market capitalization near $57.2M, listed on NASDAQ, employing roughly 4 people, carrying a beta of 0.04 to the broader market. OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Led by Robert J. Dempsey, public since 2022-05-17.
Max pain analysis shows the strike price where the most options expire worthless. No recent options activity for OKYO as of 2026-07-17; this typically reflects low options liquidity, a recently listed name, or a temporary data feed delay. Snapshot will refresh on the next active session.